ArticleGastroenterology research and practice2023

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study.

Anat Fisher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.